ÀÌ½ÄÆí´ë¼÷ÁÖº´(GVHD) ½ÃÀå : Áúº´ À¯Çüº°, Ä¡·á À¯Çüº°, ¿¬·É´ëº°, Åõ¿© °æ·Îº°, À¯Åë ä³Îº° - ¼¼°è ¿¹Ãø(2024-2032³â)
Graft Versus Host Disease (GVHD) Market - By Disease Type, Treatment Type, Age Group, Route of Administration, Distribution Channel - Global Forecast 2024 - 2032
»óǰÄÚµå : 1495575
¸®¼­Ä¡»ç : Global Market Insights Inc.
¹ßÇàÀÏ : 2024³â 03¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 160 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,850 £Ü 7,017,000
PDF & Excel (Single User License) help
PDF, Excel º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,050 £Ü 8,753,000
PDF & Excel (Multi User License) help
PDF, Excel º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,350 £Ü 12,081,000
PDF & Excel (Enterprise User License) help
PDF, Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

ÀÌ½ÄÆí´ë¼÷ÁÖº´(GVHD) ½ÃÀå ±Ô¸ð´Â ƯÈ÷ Ç÷¾×¾Ç¼ºÁ¾¾ç ¹× ÀÚ°¡¸é¿ªÁúȯ Ä¡·á¿¡¼­ Á¶Ç÷¸ð¼¼Æ÷À̽Ä(HSCT)ÀÇ Ã¤Åà Áõ°¡·Î ÀÎÇØ 2024³âºÎÅÍ 2032³â±îÁö ¿¬Æò±Õ 8.1%ÀÇ ¼ºÀå·üÀ» ±â·ÏÇÒ °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ±¹¸³º¸°Ç¿ø(National Institute of Health)¿¡ µû¸£¸é, ¿¬°£ ¾à 5¸¸ °ÇÀÇ Áٱ⼼Æ÷ À̽ÄÀÌ ÀÌ·ç¾îÁö°í ÀÖÀ¸¸ç, ¿¬°£ ¼ºÀå·üÀº 10%¿¡¼­ 15%¿¡ ´ÞÇÕ´Ï´Ù. Á¶Ç÷¸ð¼¼Æ÷ À̽ÄÀº ¿©ÀüÈ÷ ´Ù¾çÇÑ Áúº´¿¡ ´ëÇÑ Áß¿äÇÑ Ä¡·á¹ýÀ̱⠶§¹®¿¡ GVHDÀÇ ¹ß»ý·üÀº ±×¿¡ µû¶ó Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÇ·á±â¼ú°ú À̽ļúÀÇ ±Þ¼ÓÇÑ ¹ßÀüÀ¸·Î ÀÌ½Ä È¯ÀÚÀÇ »ýÁ¸À²ÀÌ Çâ»óµÇ°í ÀÖ½À´Ï´Ù.

ÀÇ·áÁø°ú ȯÀÚµéÀÇ ÀνÄÀÌ ³ô¾ÆÁü¿¡ µû¶ó GVHD °ü¸®¿¡¼­ Á¶±â ¹ß°ß°ú ½Å¼ÓÇÑ °³ÀÔÀÇ Á߿伺ÀÌ ´õ¿í ºÎ°¢µÇ°í ÀÖ½À´Ï´Ù. Àû½Ã¿¡ Áø´ÜÇϸé ÀûÀýÇÑ Ä¡·á Àü·«À» ½ÃÀÛÇÒ ¼ö ÀÖ¾î GVHDÀÇ ÁßÁõµµ¸¦ ÁÙÀ̰í ȯÀÚÀÇ ¿¹Èĸ¦ °³¼±ÇÒ ¼ö ÀÖ½À´Ï´Ù. À¯È¿¼º°ú ¾ÈÀü¼ºÀ» °³¼±ÇÑ »õ·Î¿î Ä¡·áÁ¦ °³¹ß¿¡ ÁßÁ¡À» µÐ ¿¬±¸°³¹ß Ȱµ¿ÀÌ ÁøÇàµÇ°í ÀÖ´Â °Íµµ ½ÃÀå È®´ë¸¦ ´õ¿í ÃËÁøÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.

GVHD »ê¾÷Àº Áúº´ À¯Çü, Ä¡·á À¯Çü, ¿¬·É´ë, Åõ¿© °æ·Î, À¯Åë ä³Î, Áö¿ªÀ¸·Î ±¸ºÐµË´Ï´Ù.

Ä¡·á À¯Çüº°·Î´Â ºÎ½ÅÇÇÁú ½ºÅ×·ÎÀÌµå ½ÃÀå ±Ô¸ð´Â °­·ÂÇÑ Ç׿°Áõ ¹× ¸é¿ª¾ïÁ¦ È¿°ú·Î ÀÎÇØ 2032³â±îÁö 7.8%ÀÇ ¼ºÀå·üÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ºÎ½ÅÇÇÁú ½ºÅ×·ÎÀ̵å´Â °æ±¸¿ë, Á¤¸ÆÁÖ»ç, ±¹¼Ò¿ë µî ´Ù¾çÇÑ Á¦ÇüÀ¸·Î ³Î¸® »ç¿ëµÇ°í ÀÖÀ¸¸ç, GVHDÀÇ ÁßÁõµµ ¹× ¹ßÇö ºÎÀ§¿¡ µû¸¥ Ä¡·áÀû Á¢±ÙÀ» °¡´ÉÇÏ°Ô ÇÏ´Â À¯¿¬¼ºÀ» Á¦°øÇÕ´Ï´Ù.

Åõ¿© °æ·Î Ãø¸é¿¡¼­ ÀÌ½ÄÆí´ë¼÷ÁÖº´ ½ÃÀåÀÇ °æ±¸¿ë ÀǾàǰ ºÎ¹®Àº 2024-2032³â 8.4%ÀÇ CAGRÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. °æ±¸¿ë ÀǾàǰÀº ȯÀÚ¿¡°Ô ÆíÀǼº°ú Åõ¾àÀÇ ¿ëÀ̼ºÀ» Á¦°øÇÏ¿© ÀÓ»ó ȯ°æ ¹Û¿¡¼­ ÀÚ°¡ °ü¸®¸¦ º¸ÀåÇϰí Ä¡·á ¿ä¹ý Áؼö¸¦ ÃËÁøÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ÆíÀǼºÀº ȯÀÚÀÇ ¼øÀÀµµ¸¦ ³ô¿© Ä¡·á °á°ú¿Í Àü¹ÝÀûÀÎ »îÀÇ Áú Çâ»óÀ¸·Î À̾îÁý´Ï´Ù.

¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ÀÌ½ÄÆí´ë¼÷ÁÖº´ »ê¾÷Àº 2024³âºÎÅÍ 2032³â±îÁö ¿¬Æò±Õ 8.5%ÀÇ °ý¸ñÇÒ ¸¸ÇÑ ¼ºÀåÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ´Â Á¶Ç÷¸ð¼¼Æ÷ À̽Ä(HSCT)ÀÇ ¹ßº´·üÀÌ Áõ°¡Çϰí ÀÖÀ¸¸ç, ƯÈ÷ ÀÇ·á ÀÎÇÁ¶ó°¡ Àß °®Ãß¾îÁ® ÀÖ°í ÀÌ½Ä ¼­ºñ½º¿¡ ´ëÇÑ Á¢±Ù¼ºÀÌ °³¼±µÈ ±¹°¡µé¿¡¼­ ±× ºñÀ²ÀÌ Áõ°¡Çϰí Àֱ⠶§¹®ÀÔ´Ï´Ù. ÇöÁö ÀÇ·á±â°ü, Á¦¾à»ç, ¿¬±¸±â°ü °£ÀÇ Çù·ÂÀÌ °­È­µÇ¸é¼­ ÀÓ»óÀû Çʿ信 ¸Â´Â »õ·Î¿î GVHD Ä¡·áÁ¦ÀÇ ½ÃÀå °³¹ßÀÌ ÃËÁøµÇ°í ÀÖÀ¸¸ç, ÀÌ´Â ÀÌ Áö¿ªÀÇ ½ÃÀå ¼ºÀåÀ» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú Á¶»ç ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ¾÷°è ÀλçÀÌÆ®

Á¦4Àå °æÀï »óȲ

Á¦5Àå ½ÃÀå ÃßÁ¤°ú ¿¹Ãø : Áúȯ À¯Çüº°, 2021-2032³â

Á¦6Àå ½ÃÀå ÃßÁ¤°ú ¿¹Ãø : Ä¡·á À¯Çüº°, 2021-2032³â

Á¦7Àå ½ÃÀå ÃßÁ¤°ú ¿¹Ãø : ¿¬·ÉÃþº°, 2021-2032³â

Á¦8Àå ½ÃÀå ÃßÁ¤°ú ¿¹Ãø : Åõ¿© °æ·Îº°, 2021-2032³â

Á¦9Àå ½ÃÀå ÃßÁ¤°ú ¿¹Ãø : À¯Åë ä³Îº°, 2021-2032³â

Á¦10Àå ½ÃÀå ÃßÁ¤°ú ¿¹Ãø : Áö¿ªº°, 2021-2032³â

Á¦11Àå ±â¾÷ °³¿ä

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Graft versus host disease (GVHD) market size is estimated to register 8.1% CAGR between 2024 to 2032, driven by the increasing adoption of hematopoietic stem cell transplantation (HSCT) procedures, particularly in the treatment of hematologic malignancies and autoimmune disorders. As per National Institute of Health, approximately 50,000 stem cell transplants are conducted annually, experiencing an annual growth rate ranging between 10% to 15%. As HSCT remains a crucial treatment modality for various diseases, the incidence of GVHD is expected to rise correspondingly. Rapid advancements in medical technology and transplant procedures have led to improved survival rates among transplant recipients.

Increased awareness among healthcare providers and patients is further outlining the importance of early detection and prompt intervention in GVHD management. Timely diagnosis allows the initiation of appropriate treatment strategies, thereby reducing the severity of GVHD and improving patient outcomes. The ongoing R&D activities focused on the development of novel therapeutics with improved efficacy and safety profiles will further propel the market expansion.

The GVHD industry is segmented into disease type, treatment type, age group, route of administration, distribution channel and region.

Based on treatment type, the market size from the corticosteroids segment is anticipated to witness 7.8% growth rate through 2032, due to their potent anti-inflammatory and immunosuppressive properties. Corticosteroids are widely available in various formulations, including oral, intravenous, and topical preparations for offering flexibility in administration and enabling tailored treatment approaches based on the severity and site of GVHD manifestations.

With regards to route of administration, the oral segment in the graft versus host diseases market is anticipated to observe 8.4% CAGR during 2024-2032. Oral medications offer patients convenience and ease of administration ensuring self-management outside of clinical settings and promoting adherence to treatment regimens. This accessibility is enhancing patient compliance while leading to improved treatment outcomes and overall quality of life.

Asia Pacific graft versus host disease industry will record impressive growth at 8.5% CAGR over 2024-2032. This can be attributed to the rising incidence of hematopoietic stem cell transplantation (HSCT) procedures, particularly in countries with growing healthcare infrastructure and improved access to transplant services. Rising collaborations between local healthcare institutions, pharmaceutical companies, and research organizations is fostering the development of novel GVHD therapies tailored to the clinical needs, further stimulating the regional market growth.

Table of Contents

Chapter 1 Methodology & Scope

Chapter 2 Executive Summary

Chapter 3 Industry Insights

Chapter 4 Competitive Landscape, 2023

Chapter 5 Market Estimates and Forecast, By Disease Type, 2021 - 2032 ($ Million)

Chapter 6 Market Estimates and Forecast, By Treatment Type, 2021 - 2032 ($ Million)

Chapter 7 Market Estimates and Forecast, By Age Group, 2021 - 2032 ($ Million)

Chapter 8 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Million)

Chapter 9 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Million)

Chapter 10 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Million)

Chapter 11 Company Profiles

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â